Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent Plasma for Early Treatment of COVID-19
NCT04390503Phase 2Terminated
- Start
- Mar 2021
- Primary completion
- Jan 2022
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of convalescent plasma (Heinrich-Heine University, Duesseldorf) in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoints: Number of Non-Hospitalized Participants at 28 days, Number of Hospitalized Participants Requiring Supplemental Oxygen at 28 days and 1 more. Started Mar 2021; status: terminated.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04390503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04390503.